Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal Cancer
Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.
Source: onclive.com
Stay updated with breaking news from Solid Tumor Service. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.
Scientists Awarded For Cancer Research .